Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06595160 · ClinicalTrials.gov registry record
Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy
A clinical trial of Resectable Pancreatic Ductal Adenocarcinoma and Stage I Pancreatic Cancer AJCC v8, sponsored by Emory University.
- Recruiting
- Registry status
- 87
- Enrollment target
- 1
- Study location
NCT06595160: Recruiting study of Resectable Pancreatic Ductal Adenocarcinoma and Stage I Pancreatic Cancer AJCC v8, sponsored by Emory University.
NCT06595160 is a study of Resectable Pancreatic Ductal Adenocarcinoma and Stage I Pancreatic Cancer AJCC v8 that is actively recruiting participants, run by Emory University. The registered enrollment target is 87 participants, above the 79-participant average among 5 other Resectable Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (10% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06595160, a study of Resectable Pancreatic Ductal Adenocarcinoma and Stage I Pancreatic Cancer AJCC v8, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- 87 participants
- Enrollment target
- 1
- Study location
Study Summary
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
Primary Outcome
Continuous variables will be presented as median with interquartile range and categorical variables will be presented as frequencies. Univariate logistic regression will be used to compare alpha diversity (mean inverse Simpson index) and relative abundance of operational taxonomic units up to species level in PDAC patients with and without major pathological response to neoadjuvant chemotherapy. Multivariable logistic regression analyses will be performed to identify significant factors associat
Conditions Studied
Interventions
- OTHER Non-Interventional Study
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2027-08-07 |
What NCT06595160 shows while recruiting
NCT06595160 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 87 participants, a relatively small participant target, above the 79-participant average among 5 other Resectable Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (10% higher).
The record links to 3 conditions, with Resectable Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.
NCT06595160 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06595160 about?
NCT06595160 is a clinical study titled "Determining the Link Between Dietary Patterns, Fecal Microbiome and Response to Neoadjuvant Chemotherapy". This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
What is the current status of trial NCT06595160?
This trial is currently recruiting. The enrollment target is 87 participants. The study started on 2024-08-05. Estimated completion is 2027-08-07.
What conditions does trial NCT06595160 study?
This clinical trial studies the following conditions: Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Borderline Resectable Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06595160?
The interventions under investigation include: Non-Interventional Study (OTHER).
Who is sponsoring clinical trial NCT06595160?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06595160 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Resectable Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
RECRUITING · Early Phase 1
-
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
RECRUITING · Phase 2
-
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
A Phase II Study of Neoadjuvant FOLFIRINOX
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI